The Select Study: a Multicenter Phase II Trial of Adjuvant Erlotinib in Resected Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

摘要

Adjuvant chemotherapy for NSCLC results in modest improvements, with an OS benefit of approximately 5-10% seen at 5 years, which is predominantly in stage II and III NSCLC. However, many patients still relapse after treatment with adjuvant chemotherapy. In the metastatic setting, tumors with mutations activating epidermal growth factor receptor (EGFR) are very sensitive to EGFR inhibitors. A retrospective cohort study showed a 2-year disease-free survival (DFS) of 89% in patients whose EGFR-mutant tumors were treated with erlotinib or gefkinib versus 72% in untreated patients.